(Q37665068)

21 August 2017

Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? (English)

1 reference

21 August 2017

1 reference

Richard J Lee

1

1 reference

PMCID

3966545

21 August 2017

Matthew R Smith

series ordinal

2

1 reference

PMCID

3966545

21 August 2017

language of work or name

English

0 references

publication date

27 November 2013

1 reference

21 August 2017

Clinical Cancer Research

1 reference

21 August 2017

20

1 reference

21 August 2017

525-527

1 reference

21 August 2017

3

1 reference

Cabozantinib in progressive medullary thyroid cancer

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3966545

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3966545

Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3966545

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3966545

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3966545

10.1158/1078-0432.CCR-13-2636

6 September 2017

Identifiers

DOI

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

PMCID

3966545